These three analyst rating faults are the antithesis of what biotech investors need to be successful.
News & Analysis: Prana Biotechnology
See which companies suffered the worst clinical setbacks in the week ending April 4.
Three clinical data disappointments, one biotech's wild ride, and a global biopharma's oncology data deluge highlight this week's top biotech stories.
As Q1 comes to a close, here's how it all shook out for investors. Plus, four stocks making big moves on Monday's market, and why our analysts are watching Microsoft and CBS Outdoor today.
Panera gets an upgrade, and Delta partners with Virgin Atlantic. Here are four stocks making big moves on Monday's market.
Shares of Prana were absolutely crushed today, after a phase 2 failure for its Alzheimer's drug.
Is this meaningful or just another movement?
Exelixis, Vertex Pharmaceuticals, and Prana Biotechnology expect to release data this year.
Which health-care stocks sizzled this week? Find out in our weekly rankings.
One biotech and one player in the new marijuana industry that fell hard today.